References
- Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leuk 2021;35935:2592–2601. https://www.nature.com/articles/s41375-021-01183-8 InternetAvailable from: [cited 2022 May 12].
- James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148. http://www.nature.com/articles/nature03546 InternetAvailable from: [cited 2019 Apr 27].
- Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397. https://pubmed.ncbi.nlm.nih.gov/15837627/ InternetAvailable from: [cited 2020 Jul 26].
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061. https://pubmed.ncbi.nlm.nih.gov/15781101/ InternetAvailable from: [cited 2020 Jul 26].
- Hasselbalch HC, Silver RT. New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms. Hemasphere. 2021 [[cited 2022 Nov 28]];5:e645. InternetAvailable from: /pmc/articles/PMC8601345/.
- Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN landmark survey. Cancer. 2017;123:449–458.
- Grunwald MR, Stein BL, Boccia RV, et al. Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. InternetAvailable from. 2018 [[cited 2021 Jun 20]];18:788–795.e2. DOI:10.1016/j.clml.2018.08.009
- Silver RT, Erdos K, Taylor E, et al. Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. Leukemia [Internet]. 2022 [cited 2023 Jan 29]; Available from: https://pubmed.ncbi.nlm.nih.gov/36550213/.
- Merrill EW. Rheology of blood. Physiol Rev. 1969;49:49 863–888.
- Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics [internet]. Semin Thromb Hemost. 2003;1(212):584–4662–450435–450. cited 2020 Aug 7. Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: ++ Available from: http://www.thieme-connect.de/doi/doi?10.1055/s-2003-44551
- Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood Elsevier BV. 2021;137:2152–2160.
- Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 2015;126:560–561. https://ashpublications.org/blood/article/126/4/560/34552/White-blood-cell-counts-and-thrombosis-in InternetAvailable from: [cited 2022 Jun 13].
- Ronner L, Podoltsev NA, Gotlib J, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis: an analysis from a 520-patient retrospective multi-center database. Blood. 2019;134:2949.
- Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019;3:1729. /pmc/articles/PMC6560342/ InternetAvailable from: [cited 2022 Nov 29].
- Abu-Zeinah G, Krichevsky S, Silver RT, et al. A novel machine learning-derived dynamic scoring system predicts risk of thrombosis in polycythemia vera (PV) patients. Blood. 2021;138:3619.
- Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2012;121:360–368.
- Teofili L, Martini M, Iachininoto MG, et al. Endothelial progenitor cells are clonal and exhibit the JAK2 V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood. 2011;117:2700–2707.
- Etheridge SL, Roh ME, Cosgrove ME, et al. JAK2V 617 F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci. 2014;111:2295–2300.
- Sozer S, Fiel MI, Schiano T, et al. Brief report the presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2016;113:5246–5250.
- Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. InternetAvailable from. 2013 [[cited 2020 Aug 20]];368:22–33. DOI:10.1056/NEJMoa1208500
- Santisakultarm TP, Paduano CQ, Stokol T, et al. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014;12:2120–2130.
- Najean Y, Dresch C, Rain J‐D. The very‐long‐term course of polycythaemia: a complement to the previously published data of the polycythaemia vera study group. Br J Haematol. 1994;86:233–235.
- Brunner AM, Hobbs G, Jalbut MM, et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database [Internet]. Leuk Lymphoma 2016. 1197–1200. Taylor and Francis Ltd. cited 2021 Jun 19. Available from. /pmc/articles/PMC4943877/.
- Abu-Zeinah K, Saadeh K, Silver RT, et al. Excess mortality in younger patients with myeloproliferative neoplasms. Leuk Lymphoma [Internet]. 2022 [cited 2022 May 12];p. 1–5. Available from: https://www.tandfonline.com/doi/abs/10.1080/10428194.2022.2070914.
- Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia 2019;33:1996–2005. http://www.ncbi.nlm.nih.gov/pubmed/31142846 InternetAvailable from: [cited 2020 Feb 16].
- Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022;86:339–344.
- Musiałek MW, Rybaczek D. Hydroxyurea—the good, the bad and the ugly. Genes (Basel). 2021 [[cited 2022 Jun 13]];1212:1096–1096. [Internet]. 2021 Available from: https://www.mdpi.com/2073-4425/12/7/1096/htm.
- Bulte CA, Hoegler KM, Kutlu Ö, et al. Hydroxyurea: a reappraisal of its cutaneous side effects and their management. Int J Dermatol 2021;60:810–817. https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.15302 InternetAvailable from: [cited 2021 Oct 7].
- Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018;132:694–706. https://ashpublications.org/blood/article/132/7/694/39442/Aggressive-B-cell-lymphomas-in-patients-with InternetAvailable from: [cited 2022 Nov 29].
- Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507–2513. http://www.ncbi.nlm.nih.gov/pubmed/25037629 Internetquiz 2615. Available from: [cited 2019 Jun 3].
- Abu-Zeinah G, Silver RT, Abu-Zeinah K, et al. Normal life expectancy for polycythemia vera (PV) patients is possible. Leuk 2021;36:569–572. https://www.nature.com/articles/s41375-021-01447-3 InternetAvailable from: [cited 2022 May 12].
- Zoi K, Cross NCP. Genomics of myeloproliferative neoplasms. J Clin Oncol. 2017;35:947–954.
- Peterson P, Ellis J. The bone marrow in polycythemia vera. In: Wasserman L, Berk P Berlin N, editors. Polycythemia vera myeloproliferative disord. Philadelphia: WB Saunders; 1995. p. 31.
- Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 2018;379:1416–1430. http://www.nejm.org/doi/10.1056/NEJMoa1716614 InternetAvailable from: [cited 2019 Jan 30].
- Broséus J, Park JH, Carillo S, et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014;124:3964–3966. http://ashpublications.org/blood/article-pdf/124/26/3964/1465406/3964.pdf InternetAvailable from: [cited 2021 Jun 19].
- Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013;122:1881–1886. http://www.ncbi.nlm.nih.gov/pubmed/23900239 InternetAvailable from: [cited 2019 Jun 3].
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405. http://www.ncbi.nlm.nih.gov/pubmed/27069254 InternetAvailable from: [cited 2019 May 18].
- Goldman JJ, Vandris K, Adriano F, et al. Normal serum-erythropoietin (S-epo) level at diagnosis of Polycythemia Vera (PV) correlates with LowJAK2V617F mutant allele burden and indicates mild phenotype. Blood 2009;114:4978. https://ashpublications.org/blood/article/114/22/4978/77254/Normal-Serum-Erythropoietin-S-epo-Level-at InternetAvailable from: [cited 2022 Jun 6].
- Silver RT, Krichevsky S, Gjoni S, et al. Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera [Internet]. Leuk. Lymphoma. Taylor and Francis Ltd; 2017 [cited 2021 Jun 19]. p. 2768–2769. Available from: https://pubmed.ncbi.nlm.nih.gov/28317411/.
- Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194–1198.
- Silver RT, Krichevsky S Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values. Haematologica [Internet]. 2019 [cited 2019 Jun 3];haematol.2018.213108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30948488.
- Abu-Zeinah G, Di Giandomenico S, Cruz T, et al. Hematopoietic stem and progenitor cell fitness as a novel prognostic and monitoring biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs). Blood. 2021;138:627.
- Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017;31:2726–2731. http://www.nature.com/articles/leu2017169 InternetAvailable from: [cited 2019 Jun 20].
- Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21:1952–1959.
- Guglielmelli P, Loscocco GG, Mannarelli C, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. InternetAvailable from 2021;11: 11.doi: 10.1038/s41408-021-00581-6
- Silver RT, Vandris K, Wang YL, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011;35:177–182. /pmc/articles/PMC3626091/?report=abstract InternetAvailable from: [cited 2020 Dec 11].
- Abu-Zeinah G, Di Giandomenico S, Choi DC, et al. Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood Adv. 2022;6:5477–5481. InternetAvailable from https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022007128/485787/Hematopoietic-fitness-of-JAK2V617F
- Stein BL, Williams DM, Rogers O, et al. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol 2011;39:95–101. https://pubmed.ncbi.nlm.nih.gov/20888389/ InternetAvailable from: [cited 2020 Dec 11].
- Margolskee E, Krichevsky S, Orazi A, et al. Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients. Haematologica 2017;102:e97–99. http://www.ncbi.nlm.nih.gov/pubmed/27810993 InternetAvailable from: [cited 2018 Sep 1].
- Abu-Zeinah G, Castillo Tokumori F, Erdos K, et al. Polycythemia vera patients with >20% reduction in whole blood JAK2V617F allele frequency have improved myelofibrosis-free survival but not overall survival. Blood. 2022;140:6819–6820.
- Guglielmelli P, Mora B, Gesullo F, et al. JAK2V617F molecular response to ruxolitinib in patients with PV and ET is associated with lower risk of progression to secondary myelofibrosis. Blood 2022;140:1788–1789. https://ashpublications.org/blood/article/140/Supplement1/1788/493219/JAK2V617F-Molecular-Response-to-Ruxolitinib-in InternetAvailable from: [cited 2022 Dec 6].
- Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol 2020;189:291–302. https://pubmed.ncbi.nlm.nih.gov/31945802/ InternetAvailable from: [cited 2021 Jan 17].
- Haferlach T. The time has come for next-generation sequencing in routine diagnostic workup in hematology. Haematologica. 2021 [[cited 2022 Dec 6]];106:659–661. InternetAvailable from: https://haematologica.org/article/view/10189.
- Vaquez H. Sur une forme speciale de cyanose s’accompanant d’hyperglobulie excessive et peristente (On a special form of cyanosis accompanied by excessive and persistent erythrocytosis). Compt Rend Soc Biol Suppl Note, Bull Mem Soc Med D’hop Paris. 1892;4:384–388.
- Osler W. Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci. 1903;126:187–201.
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. 2022 [cited 2023 Jan 29];36:1703–1719. Leuk 2022 367 [Internet] Available from https://www.nature.com/articles/s41375-022-01613-1.
- Silver RT, Gjoni S. The hematocrit value in polycythemia vera: caveat utilitor. Leuk Lymphoma. 2015 [[cited 2022 Jun 6]];56:1540–1541. InternetAvailable from: https://www.tandfonline.com/doi/abs/10.3109/10428194.2014.966243.
- Spivak JL, Silver RT. The revised world health organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008 [[cited 2020 Sep 28]];112:231–239. InternetAvailable from: http://ashpublications.org/blood/article-pdf/112/2/231/1299942/zh801408000231.pdf.
- Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339–351. [[cited 2019 Jul 27]]. InternetAvailable from http://www.ncbi.nlm.nih.gov/pubmed/1198126
- Jacob G, Raj SR, Ketch T. Postural pseudoanemia: posture-dependent change in hematocrit. Mayo Clin Proc. 2005. [cited 2022]; 80:611–614. InternetAvailable from: https://www.mayoclinicproceedings.org/article/S0025-6196(11)63092-9/fulltext
- Berlin NI. Classification of the polycythemias and initial clinical features in polycythemia vera. In: Wasserman L, Berk P, and Berlin N, editors. Polycythemia vera and the myeloproliferative disorders. Philadelphia: WB Saunders; 1995. p. 22–30.
- Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005 [[cited 2022 Dec 6]];129:701–705. InternetAvailable from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2005.05517.x.
- Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the “early” prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008;130:336–342. https://pubmed.ncbi.nlm.nih.gov/18701405/ InternetAvailable from: [cited 2021 Jun 19].
- Kvasnicka HM, Orazi A, Thiele J, et al. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017;92:1062–1067.
- Hasselbalch HC. Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera? Haematologica. 2019 [[cited 2023 Jan 29]];104:2119. InternetAvailable from: /pmc/articles/PMC6821626/.
- Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200–1228. https://pubmed.ncbi.nlm.nih.gov/35767897/ InternetAvailable from: [cited 2023 Jan 29].
- Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 2008;22:452–453. https://www.nature.com/articles/2404908 Leuk 2007 222 [Internet] Available from: [cited 2022 Dec 6].
- Chievitz E, Thiede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962 [[cited 2020 Aug 20]];172:513–523. InternetAvailable from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.0954-6820.1962.tb07186.x.
- Spivak JL. Myeloproliferative neoplasms. Longo D editor. N Engl J Med. 2017. InternetAvailable from. [cited 2022 Jan 3];376:2168–2181. https://www-nejm-org.ezproxy.med.cornell.edu/doi/10.1056/NEJMra1406186.
- Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006 [[cited 2018 Jul 28]];107:451–458. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/16804923
- Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132–143.
- Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 2017;102:103–109. https://pubmed.ncbi.nlm.nih.gov/27686377/ InternetAvailable from: [cited 2022 Dec 6].
- Barbui T, Carobbio A, Ghirardi A, et al. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European collaboration on low-dose aspirin in polycythemia vera and cytoreductive therapy in polycythemia vera clinical trials. Haematologica 2017;102:e219. /pmc/articles/PMC5451347/ InternetAvailable from: [cited 2022 Dec 6].
- Hoffman R, Ginzburg Y, Kremyanskaya M, et al. Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients.
- Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018;32:1057–1069. http://www.ncbi.nlm.nih.gov/pubmed/29515238 InternetAvailable from: [cited 2018 Sep 19].
- Ali H, Bose P, Dunbar A, et al. NCCN Guidelines, Myeloproliferative Neoplasms, version 2. 2022.
- Carl Hasselbalch H, Stauffer Larsen T, Hasselbalch Riley C, et al. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 2011;12:392–419. https://pubmed.ncbi.nlm.nih.gov/21143149/ InternetAvailable from: [cited 2023 Jan 29].
- Barbui T, Masciulli A, Carobbio A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Artic Lancet Haematol 2021;8:175–184. www.thelancet.com/haematology InternetAvailable from: [cited 2021 Apr 5].
- Song J, Sergueeva A, Miasnikova G, et al. Phlebotomy-induced iron deficiency increases the expression of prothrombotic genes. Blood. 2020;136:11–12.
- Al-Samkari H, Kessler CM, Auerbach M. Recognition of thrombotic risk of thrombocytosis in iron deficiency. Haematologica. 2021 [[cited 2022 Dec 6]];106:661–663. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/33645945/.
- Mesa R, Boccia RV, Grunwald MR, et al. Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:590–596.
- Tefferi A, Ianotto JC, Mathews V, et al. Myeloproliferative neoplasms – a global view. Br J Haematol 2022;198:953–964. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18213 InternetAvailable from: [cited 2023 Jan 29].
- Goulart H, Mascarenhas J, Tremblay D. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions. Ann Hematol. 2022 [[cited 2023 Jan 29]];101:935–951. InternetAvailable from: https://link.springer.com/article/10.1007/s00277-022-04826-7.
- Rector WG, Fortuin NJ, Conley CL. Non-hematologic effects of chronic iron deficiency. A study of patients with polycythemia vera treated solely with venesections. Medicine (Baltimore). 1982 [[cited 2022 Dec 6]];61:382–389. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/7144531/.
- Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences [Internet]. Leuk Nature Publ Group. [ Available from]. 2018 [cited 2021 Jun 19];32:2105–2116. DOI:10.1038/s41375-018-0207-9.
- Von Drygalski A, Adamson JW. Ironing out fatigue. Blood. 2011 [[cited 2023 Jan 29]];118:3191–3192. InternetAvailable from: https://ashpublications.org/blood/article/118/12/3191/28774/Ironing-out-fatigue
- Marchetti M, Maria Vannucchi A, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 2022;9:e301–311. www.thelancet.com/haematologyVol InternetAvailable from: [cited 2022 Jul 25].
- Triguero A, Pedraza A, Pérez-Encinas M, et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish registry of polycythemia vera. Ann Hematol 2022;101:2231–2239. https://pubmed.ncbi.nlm.nih.gov/36042023/ InternetAvailable from: [cited 2022 Dec 29].
- Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441–447.
- Björkholm M, Derolf ÅR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410–2415.
- Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol 1984;17:329–334. http://www.ncbi.nlm.nih.gov/pubmed/6496458 InternetAvailable from: [cited 2020 Mar 20].
- Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol 2017;92:1131–1136. https://pubmed.ncbi.nlm.nih.gov/28699191/ InternetAvailable from: [cited 2020 Oct 5].
- Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:417–421. http://www.thieme-connect.de/doi/doi?10.1055/s-2006-942762 InternetAvailable from: [cited 2020 Mar 19].
- Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370–3377.
- Arlt MF, Ozdemir AC, Birkeland SR, et al. Hydroxyurea induces de novo copy number variants in human cells. Proc Natl Acad Sci U S A. InternetAvailable from. 2011 [[cited 2022 Jun 13]];108:17360–17365. DOI:10.1073/pnas.1109272108
- Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 2018;24:1015–1023. https://www-nature-com.ezproxy.med.cornell.edu/articles/s41591-018-0081-z InternetAvailable from: [cited 2022 Jan 9].
- Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Available from: https://cancer.sanger.ac.uk/cosmic.
- Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 2018;36:310–318. http://ascopubs.org/doi/10.1200/JCO.2017.76.4886 InternetAvailable from: [cited 2019 Jun 30].
- Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975 [[cited 2021 Oct 7]];111:183–187. InternetAvailable from: https://jamanetwork.com/journals/jamadermatology/fullarticle/534766.
- Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11:403–414.
- Liu D, Xu Z, Zhang P, et al. Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center. Haematologica. InternetAvailable from. 2022 [[cited 2023 Jan 29]];107:991–995. DOI:10.3324/haematol.2021.280080
- Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–375.
- Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon AlphaA In chronic myelogenous leukemia. N Engl J Med. 1986;314:1065–1069. Internet[cited 2022 Jun 13];314:10651069. Available from . Internet[cited 2022 Jun 13];314:10651069. Available from https://www.nejm.org/doi/10.1056/NEJM198604243141701
- Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet (London, England. Lancet. 1988 [[cited 2018 Nov 3]];2:403. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/2899816.
- Silver RT. Interferon-α2b: a new treatment for polycythemia vera. Ann Intern Med. 1993 [[cited 2021 Jan 12]];119:1091–1092. InternetAvailable from: https://annals.org
- Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera. Blood. 2013;121:3692–3703. InternetAvailable from http://www.ncbi.nlm.nih.gov/pubmed/23487027
- Skov V, Thomassen M, Kjær L, et al. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLoS ONE 2022;17:e0270669. /pmc/articles/PMC9246201/ InternetAvailable from: [cited 2022 Dec 30].
- Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418–5424. https://pubmed.ncbi.nlm.nih.gov/19826111/ InternetAvailable from: [cited 2020 Dec 11].
- Lengfelder E, Berger U, Hehlmann R. Interferon α in the treatment of polycythemia vera. Ann Hematol. 2000;79:103–109.
- Tefferi A, Elliott MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 2001;97:1896.
- Bewersdorf JP, Giri S, Wang R, et al. Chronic myeloproliferative neoplasms Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. InternetAvailable from. 2021 [[cited 2022 Jan 17]];35:1643–1660. DOI:10.1038/s41375-020-01020-4
- Illés Á, Pinczés LI, Egyed M. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Expert Opin Drug Metab Toxicol. 2021 [[cited 2022 Dec 30]];17:3–7. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/33118413/
- Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013;122:893–901. http://www.ncbi.nlm.nih.gov/pubmed/23782935 InternetAvailable from: [cited 2018 Sep 20].
- Kiladjian JJ, Klade C, Georgiev P, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leuk 2022;36:1408–1411. https://www.nature.com/articles/s41375-022-01528-x InternetAvailable from: [cited 2022 Jun 13].
- Pizzi M, Silver RT, Barel A, et al. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015;28:1315–1323. InternetAvailable from. DOI:10.1038/modpathol.2015.93.
- Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol Taylor & Francis. 2013;6:49–58.
- Silver RT, Kiladjian JJ, Hasselbalch HC Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis [Internet]. Expert Rev. Hematol. Taylor & Francis; 2013 [cited 2021 Jan 14]. p. 49–58. Available from: https://www.tandfonline.com/doi/abs/10.1586/ehm.12.69.
- Hasselbalch HC, Silver RT Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? [Internet]. Expert Rev. Hematol. Taylor and Francis Ltd; 2015 [cited 2020 Nov 27]. p. 439–445. Available from: https://pubmed.ncbi.nlm.nih.gov/25996953/.
- Silver RT, Hasselbalch HC. Optimal therapy for polycythemia vera and essential thrombocythemia: preferred use of interferon therapy based on phase 2 trials. Hematology. 2016;21:387–391. InternetAvailable from. DOI:10.1080/10245332.2015.1111644.
- Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–208.
- Gisslinger H, Klade C, Georgiev P, et al. S196: rOPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS in POLYCYTHEMIA VERA: fINAL RESULTS from the PROUD-PV/CONTINUATION-PV STUDIES. Hemasphere 2022;6:97–98. https://journals.lww.com/hemasphere/Fulltext/2022/06003/S196__ROPEGINTERFERON_ALFA_2B_ACHIEVES.97.aspx InternetAvailable from: [cited 2022 Aug 13].
- Heibl S. Is it time for interferon in low-risk patients with polycythaemia vera? Lancet Haematol. 2021 [[cited 2022 Jun 13]];8:e162–163. InternetAvailable from: http://www.thelancet.com/article/S2352302620304348/fulltext.
- Ali H, Bose P, Dunbar A, et al. NCCN guidelines version 2.2022 myeloproliferative neoplasms. 2022 [cited 2022 Jul 25]; Available from: https://www.nccn.
- Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood. 2022 [[cited 2023 Jan 29]];139:2871–2881. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/35271702/.
- Podoltsev NA, Zhu M, Zeidan AM, et al. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv 2018;2:2681–2690. https://pubmed.ncbi.nlm.nih.gov/30333100/ InternetAvailable from: [cited 2020 Nov 30].